{
    "clinical_study": {
        "@rank": "40053", 
        "arm_group": {
            "arm_group_label": "Female Patients with D-IBS", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of YM060 once daily for female patients with\n      diarrhea-predominant irritable bowel syndrome (D-IBS) for a long-term period (up to 52\n      weeks)."
        }, 
        "brief_title": "A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diarrhea-predominant Irritable Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Diarrhea", 
                "Irritable Bowel Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Female patients who meet the following criteria:\n\n          1. Patients satisfying the Rome III Diagnostic Criteria\n\n          2. Patients whose \u226525% of stools were loose or watery and <25% of them were hard or\n             lumpy stools\n\n          3. Patients who have abdominal pain or discomfort\n\n          4. Patients in whom after occurrence of IBS symptoms the following tests were conducted\n             and in whom no organic changes were observed Pancolonoscopy or contrast enema\n\n        Exclusion Criteria:\n\n        Patients who meet any of the following criteria:\n\n          1. Patients with a history of surgical resection of the stomach,gallbladder, small\n             intestine or large intestine\n\n          2. Patients with a history or current evidence of inflammatory bowel disease\n\n          3. Patients with a history or current evidence of colitis ischemic\n\n          4. Patients with concurrent infectious enteritis\n\n          5. Patients with concurrent hyperthyroidism or hypothyroidism\n\n          6. Patients with concurrent active peptic ulcer\n\n          7. Patients with other concurrent disease that may affect the digestive tract passage or\n             large intestinal function or that is likely to interfere with proper assessment of\n             IBS abdominal pain/discomfort"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "151", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736423", 
            "org_study_id": "060-CL-703"
        }, 
        "intervention": {
            "arm_group_label": "Female Patients with D-IBS", 
            "description": "oral", 
            "intervention_name": "YM060", 
            "intervention_type": "Drug", 
            "other_name": "Ramosetron"
        }, 
        "intervention_browse": {
            "mesh_term": "Ramosetron"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "YM060", 
            "Ramosetron", 
            "long term study", 
            "Diarrhea-predominant Irritable Bowel Syndrome", 
            "Female"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Monthly responder rate of global assessment of relief of overall IBS symptoms", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Monthly responder rate of stool form normalization", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Monthly responder rate of global assessment of relief of abdominal pain/discomfort", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Monthly responder rate of global assessment of improvement of abnormal bowel habits", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Change in weekly average of scores of severity of abdominal pain/discomfort", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Change in weekly average of scores of stool form", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Change in weekly average of stool frequency", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Rate of days without urgency", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Rate of days without feeling of incomplete bowel movement", 
                "safety_issue": "No", 
                "time_frame": "up to 52 weeks"
            }, 
            {
                "measure": "Change in entire Japanese version of Irritable Bowel Syndrome Quality of Life (IBS-QOL-J) scores and pairwise IBS-QOL-J scores on the sub-scales", 
                "safety_issue": "No", 
                "time_frame": "4, 8, 12, 28 and 52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736423"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety assessed through AEs and clinical laboratory values", 
            "safety_issue": "No", 
            "time_frame": "up to 52 weeks"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}